Navigation Links
New Collagen Meniscus Implant Opens New Vista for Knee Repair
Date:8/4/2009

SAN FRANCISCO, Aug. 4 /PRNewswire/ -- The Stone Clinic in San Francisco reported it implanted the first commercially available meniscus templates in California this past week, opening up a whole new field of meniscus reconstruction. The implant permits segmental rebuilding of portions damaged or missing meniscus cartilage, the fibrous shock absorber of the knee.

To date doctors have only been able to remove, suture repair or replace the whole meniscus with cadaver tissue. There was no method of rebuilding or regenerating missing and torn segments. Torn meniscus cartilage leads to more than 1.4 million knee arthroscopies each year in the U.S. alone. Most commonly, surgeons just remove the damage tissue leaving the knee exposed to wear and tear arthritis. The new medical procedure -- collagen meniscus implant -- literally allows meniscus cartilage in the knee to re-grow.

The patients who received the first implants -- one a women in her sixties, who hurt her knee ballroom dancing, a 46-year-old chiropractor, who hurt his knee weightlifting, and a 26-year-old male who hurt his knee surfing -- were able to resume physical therapy on day one after surgery.

"This new implant is similar to a rose trellis, acting as a guide for the new tissue growth," said Kevin R. Stone MD, who heads the Stone Clinic. "The implant temporarily replaces the damaged meniscus and literally becomes part of the body. There are no artificial devices. The collagen implant is a temporary template and serves as a scaffold for tissue re-growth."

Many patients with healthy knees, but who are missing a portion of their meniscus, will benefit from a segmental re-growth, Dr. Stone said. The device is the only one engineered for patients missing meniscus tissue. It is also a great augmentation device for difficult-to-repair meniscus tears, such as bucket-handle tears and horizontal cleavage tears with missing volume.

This new implant which Stone calls a "regeneration template" was invented by him in 1986 and used in his first human patient trial in 1990, but then took a lengthy course through the FDA. The implant marketed by ReGen Biologics Inc. and called "Menaflex" received recent press for the way the FDA handled the approval process.

ABOUT THE STONE CLINIC

The Stone Clinic treats people with injuries from all over the world. Athletes and people with arthritis seek out the clinic's expertise in ligament, articular cartilage and meniscus repair, regeneration and replacement and help people return to activities. For more information, see www.stoneclinic.com.

Background

Meniscus Reconstruction with Tissue Engineering Can Be a Knee Saver

Twenty-five years ago, orthopedic surgeon Kevin R. Stone, MD, of The Stone Clinic in San Francisco, answered the challenge of his mentor: "If you could replace the meniscus cartilage, you would make a big contribution to people's lives." This week, that challenge came to fruition when Stone implanted the first commercially available collagen meniscus implant into the knees of two patients. The journey from medical challenge to medical solution has not been easy.

"Early on, I realized that I could not replace the meniscus with artificial material because no artificial material was soft enough, yet durable and slick enough not to damage the opposing articular cartilage in peoples' knees," Stone said. "So, I sought to re-grow the meniscus and did so in 1986 by designing the first tissue engineering product in orthopedics: the collagen meniscus implant." Stone, who won the International Society of the Knee's Albert Trillat Young Investigator's Award for his meniscus regeneration work in 1989 and then the American Orthopedics Society for Sports Medicine's Cabaud Award in 1990, never imagined the process would take 22 years from invention to FDA-approval in the U.S.

The implant, now marketed by ReGen Biologics, Inc., the company Stone co-founded with colleague Richard Steadman M.D., in 1989, underwent a tortuous course. The initial clinical trial in 10 patients was completed at The Stone Clinic in San Francisco in the early 1990s with successful results. Trials were repeated again with successful results, leading to a wide clinical trial in the U.S. and approval in Europe where more than 3,000 implants have already been performed. The U.S. trial and gaining FDA approval took until the end of 2008. Now, over 20 years later, Stone has the joy of implanting his device in his own patients.

"We have become very skilled at complete replacement of the meniscus cartilage with allograft menisci, even in patients with arthritis," Stone said. "However, many patients with healthy knees - but who are still missing a portion of their meniscus - will benefit from a segmental re-growth. The device is perfectly engineered for this type of procedure. It is also a great augmentation device for difficult-to-repair meniscus tears, such as bucket-handle tears and horizontal cleavage tears with missing volume. Stone added, "This week, we also used the collagen meniscus implant as a growth factor carrier for platelet-rich plasma to augment the body's ability to regenerate tissue in a chronic bucket-handle tear in a young athlete. I expect it will also be a great stem cell carrier."

Stone's medical odyssey demonstrates how long the process of invention can be, but the outcome is worth it for those willing to persevere.

For more information see: www.stoneclinic.com.

    The Stone Clinic
    3727 Buchanan Street
    San Francisco, CA 94123
    415 563 3110
    info@stoneclinic.com


'/>"/>
SOURCE The Stone Clinic
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for SynOss(TM) Synthetic Mineral Bone Graft Material
2. AGI Dermatics Data Indicates 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1, Increases Collagen and Enhances DNA Repair
3. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
4. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
5. Galderma Completes Tender Offer for CollaGenex
6. New Injectable Collagen Filler Offers Natural Results
7. Collagen VI may help protect the brain against Alzheimers disease
8. Collagen injections can help some incontinence patients when surgery fails, researcher finds
9. Study of 137 Meniscus Transplant Procedures in Patients with Arthritis is Presented to the Meniscus Transplantation Study Group at the American Academy of Orthopaedic Surgeons Annual Meeting
10. Nanowire coating for bone implants, stents
11. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Early this week, Team Iconic at J. Walter Thompson ... as the first global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé ... their product, through activities that focus on better farming, better lives and better cocoa. ...
(Date:2/10/2016)... ... ... As part of its ongoing series of aquatic therapy related webinars, HydroWorx ... dynamic expert and thoughtful presentation to give attendees a better sense of how to ... free to attend, but registration is required. , Rehabilitation of Offensive Lineman ...
(Date:2/10/2016)... ... February 10, 2016 , ... Emergency rooms provide emergency ... find. Unfortunately, this can leave patients with dental emergencies at risk of losing a ... offering emergency dental care. , Common dental emergencies include:, , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... will bring together more than 200 of the country’s top healthcare executives to ... , “The true benefit of the Forum is the provider-centric perspective, experience, expertise ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 10, 2016  Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ... reverse split of its issued and outstanding shares of ... Thursday, February 11, 2016. The Company,s common stock will ... 76303T308 and temporary ticker symbol "RCHAD". After 20 trading ... ticker symbol (RCHA).  --> ...
(Date:2/10/2016)... 2016  Oxis International Inc. (OTC/QB: OXIS) announced today ... as a "clinical trial triumph" after one of the ... cancer remission. Daniel Vallera , a ... Center. --> Daniel Vallera , a ... Center. --> An article on the ...
(Date:2/10/2016)... Feb. 10, 2016  The ALS Association, in partnership with ... Challenge to generate a biomarker to track TDP43 aggregation. The ... to a $1 million investment. --> ... that affects nerve cells in the brain and the spinal ... and control muscle movement, which often leads to total paralysis ...
Breaking Medicine Technology: